"A professional advanced organic chemistry education and pharmaceutical research platform for students and researchers."
To bring a new drug to market is a complex and highly regulated process.
Before a medicine becomes ready to use for the patients, it undergoes an extensive research, testing, and regulatory evaluation process.
This is to ensure the safety, efficacy, and quality of the drug.
In this context, one of the most important milestones in this journey is the New Drug Application (NDA) submission.
In the pharmaceutical industry, a number of organizations work collaboratively in the search and development of safe medicines.
Large organizations work on the big picture to solve the problems; however, the smaller organizations work on technical precision and flexibility.
The small organizations play a crucial role in the pharmaceutical developments. They provide technical support in chemical synthesis and analytical method developments.
Specifically the small organisations are helpful for
Thus, the small organizations provide their indirect contributions to global healthcare innovations.
What are forced degradation studies?
Here in the following video a step-by-step explanation is given. This provides a brief overview of forced degradation studies, their impact, and their importance in the regulatory submissions of the drug products. This is helpful for the graduate students and industry professionals who want to pursue a career in the field of pharmaceuticals.
This video answers following questions:
What are API impurities?
What are the forced degradation studies?
What is the need for forced degradation studies for the new drug product?
What are the analytical tools required for these studies?
What is the impact of forced degradation studies?
Regulatory agencies expect a robust impurity control strategy. The control strategy has a direct impact on drug safety, approval timelines, and lifecycle management. Therefore, chemistry graduates and regulatory professionals must understand how impurity control integrates into Drug Master File (DMF) submissions. Impurities arise from synthesis, degradation, or storage conditions. Even trace levels of impurities can affect safety and efficacy. Hence, regulatory agencies require detailed impurity identification, qualification, and control before approving any API.
The pharmaceutical impurities also known as API impurities are the unwanted chemical compounds that are found in drug substance or drug formulations. The impurities are formed due to stressful conditions and during the synthesis of API. These impurities are resposible for efficacy of the drug. The impurities also required for genotoxicity studies and reporing the impurity profile of API while regulatory submissions. Therefore the API impurities are essential in the process of drug development and manufacturing in the pharmaceutical industries.
Due to these reason the API impurities are synthezised perposely by using various chemical process. Amoung these methods Forced degredation of API is one of the most common method which is used by the researcher and pharmacetical organizations.